RadioMedix

#Drug discovery #Oncology #RadioMedix #Radiopharmaceuticals

The challenges and advancements in radiopharmaceuticals

DDW Editor Reece Armstrong speaks to Dr Ebrahim Delpassand, CEO of RadioMedix, about scaling access to radiopharmaceuticals and the company’s attempt to innovate in hard-to-treat cancers. RA: Could you discuss RAHA-100 and your goal of democratising access to the 212Pb isotope – why is this important?    ED: One of the central challenges in radiopharmaceutical targeted alpha therapy… Read More

#Exclusive Content

Peptide
#Endocrinology #FDA #Oncology #Orano Med #RadioMedix #Radiopharmaceuticals

First targeted alpha therapy receives breakthrough designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedix is a targeted alpha therapy currently in… Read More

#Cancer Research #News #Regulatory